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Amphiregulin (AREG) is an epidermal growth factor receptor ligand that can restore
integrity to damaged intestinal mucosa in murine models of acute graft-versus-host
disease (aGVHD). We previously reported that circulating AREG is elevated in late-onset
aGVHD (occurring after 100 days posttransplant), but its clinical relevance in the
context of aGVHD risk is unknown. We measured AREG in 251 aGVHD onset blood
samples from Blood and Marrow Clinical Trials Network (BMT CTN) primary
treatment trials and determined their association with GVHD severity, day 28 complete
or partial response (CR/PR) to ﬁrst-line therapy, overall survival (OS), and nonrelapse
mortality (NRM). Every doubling of plasma AREG was associated with a 33% decrease
in the odds of day 28 CR/PR (odds ratio [OR], 0.67; P, .01). An AREG threshold of 33 pg/mL
or greater divided patients with Minnesota standard-risk (SR) aGVHD into a distinct
group with a signiﬁcantly lower likelihood of: day 28 CR/PR (72% vs 85%; P 5 .02);
greater 2-year NRM (42% vs 15%; P , .01); and inferior OS (40% vs 66%; P , .01).
High AREG $ 33 pg/mL also stratiﬁed patients with Minnesota high-risk (HR) aGVHD:
day 28 CR/PR (54% vs 83%; P 5 .03) and 2-year NRM (53% vs 11%; P , .01), with a
trend toward inferior 2-year OS (37% vs 60%; P 5 .09). High-circulating AREG
($33 pg/mL) reclassiﬁes patients into HR subgroups and thereby further reﬁnes the
Minnesota aGVHD clinical risk score.
Submitted 12 February 2018; accepted 26 June 2018. DOI 10.1182/
bloodadvances.2018017343.
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Introduction
Amphiregulin (AREG) is an epidermal growth factor receptor
(EGFR) ligand produced by interleukin 33 (IL-33)-dependent type
2 innate lymphoid cells that can restore integrity to damaged
intestinal mucosa in murine models of chemical colitis and acute
graft-versus-host disease (aGVHD).1,2 AREG is released by
a variety of cell types, including regulatory T cells, fibroblasts,
keratinocytes, dendritic cells, CD4 T cells, neutrophils, mast cells,
eosinophils, and basophils, and is a key component of type
2 immune responses involved in epithelial repair and regeneration
after damage.3 We have previously described circulating AREG
as a biomarker of aGVHD in humans, where high levels may reflect
the host’s response to tissue damage.4 To date, AREG has not yet
been evaluated as a risk-stratification biomarker in a large cohort
of patients with new-onset aGVHD. To determine the association
of circulating AREG with severity of aGVHD, organ involvement,
response to therapy, and survival, we tested serum and plasma
samples obtained at aGVHD onset from 2 aGVHD first-line
treatment trials, Blood and Marrow Clinical Trials Network (BMT
CTN) 03025 and 0802.6 We also determined whether incorpo-
rating AREG into the revised Minnesota GVHD risk score could
further risk-stratify patients.7 The revised Minnesota GVHD risk
score was derived from GVHD organ staging in 1723 new-onset
aGVHD patients; 84% were classified as standard risk (SR).
Complete or partial response (CR/PR) at 28 days after starting
first-line systemic therapy was superior in SR (69% response)
vs Minnesota high risk (HR; 43% response). In the present
study, we tested whether circulating AREG could add prog-




Blood samples were obtained at the onset of systemic aGVHD
treatment in BMT CTN 0302 (serum) and BMT CTN 0802
(plasma), as previously reported.8 All patients from both studies
who had response data and available blood samples were included
in this analysis (N 5 251). Of the 251 patients, 133 also
had biomarker measurements for suppressor of tumorgenicity-2
(ST2) and regenerating islet-derived protein 3-a (REG3a), previ-
ously described biomarkers of aGVHD.9 Methodologic changes
following the original report on these biomarkers9 yield nonlinear
conversion in enzyme-linked immunosorbent assay results for ST2
and REG3a and thus preclude analysis of these biomarkers in all
patients due to limited sample availability. Eleven patients in the
cohorts from the 2 clinical trials had onset of aGVHD after day 100
(range, days 110-165), and removing their data had no impact on the
results (not shown); thus, we studied 96% classic-onset aGVHD and
4% late-onset aGVHD patients enrolled on the 2 prospective BMT
CTN trials. Samples from an independent cohort of patients with
late-onset aGVHD (N 5 92) were obtained from 2 other multicenter
studies from the Chronic GVHD Consortium, and the Mount Sinai
Acute GVHD International Consortium (MAGIC), as an independent
group to test the cut point defined in the samples from BMT CTN
0302/0802. Approval for this secondary analysis was obtained from
the BMT CTN and the University of Minnesota Institutional Review
Board.
Statistical analysis
The x2 test was used to perform statistical comparisons across
categorical variables. Differences in continuous variables across
categories were assessed using the Wilcoxon rank-sum tests for
nonparametric data.10 Kaplan-Meier curves were used to estimate
the probability of survival censoring patients at last follow-up or
24months posttransplant, whichever was first. Comparison of curves
was assessed by use of the log-rank test.11 The cumulative incidence
function12 was used to estimate the probability of nonrelapse
mortality (NRM), considering relapse as a competing risk and
censoring patients without relapse or mortality at last follow-up or
24 months posttransplant. Statistical comparisons of NRM curves
were assessed by use of the Gray test. Simple proportions were used
to estimate day 28 response, with the x2 test used to evaluate the
comparisons. Organ staging and grading was performed and
adjudicated in BMT CTN 0302 and 0802 according to consensus
criteria.13 Clinical risk stratification by Minnesota criteria have been
previously reported.7 AREG protein concentrations in serum (0302)
and plasma (0802) samples were determined by enzyme-linked
immunosorbent assay (R&DSystems, Minneapolis, MN) according to
the manufacturer’s instructions, with an assay sensitivity of 1.4 pg/
mL. No sample had an AREG value below the detection limit. All
samples were run simultaneously with identical standard curves and
sensitivities. Methods for quantification of ST2 and REG3a were
previously reported9; protein concentrations of AREG were com-
pared with ST2 and REG3a using Spearman Rho.14
AREG biomarker analysis
The optimal cut point for dichotomized analyses of AREG was based
on overall survival (OS) through 24 months posttransplant. This was
determined by evaluating all possible cutpoints of AREG and
choosing the value that maximized the absolute value of the
log-rank statistic. The log-rank statistic was determined using Cox
regression for the entire cohort.15 An unbiased estimate of the hazard
ratio and its appropriate significance from this cutpoint were
determined using twofold cross-validation.16,17 Twofold cross-
validation randomly splits the population into 2 equal subsets in
which an optimal cut point is obtained in each subset and then
applied under the setting of multiple regression analysis. These
cut points were then used to define HR and low risk in the
opposing subset, leading to the unbiased estimate of the hazard ratio
after stratifying the regression analysis by each subset. Subsequent
hazard ratios based on the optimal cut point from this method
were calculated, controlling for Minnesota risk, donor type
(matched sibling vs other related vs unrelated donor [URD] vs
umbilical cord blood [UCB]), and age. Age was modeled as a
continuous factor but divided by 10 so as to show the respective
increase in odds ratios (ORs) or hazards ratios per increase by decade
of age. All models were stratified by trial (0302 vs 0802) using the
procedure phreg from SAS version 9.4 (SAS Institute Inc, Cary, NC).
Other factors considered in the regression analysis included
conditioning (reduced-intensity conditioning vs myeloablative), sex
(male vs female) and diagnosis (nonmalignant vs myelodysplastic
syndrome/leukemia vs lymphoma vs other). Cox regression was used
to assess the independent effect of AREG on OS18; Fine and Gray
regression was used to assess the independent effect of AREG on
NRM.19 In regression analyses, classification by the 4 levels of AREG
andMinnesota risk was used to discriminate the impact and significance
of the predictive significance of AREG. To further support the
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association between AREG and our end points, regardless of an optimal
cut point, we investigated the continuous effect of AREG on clinical end
points after a log transformation base 2, allowing an interpretation of the
odds or risk of response per a doubling in the value of AREG. SAS
version 9.4 and R version 3.4.3 were used for all statistical analyses.
Results
Characteristics of the patients from BMT CTN 0302/0802 were
previously reported.8 Fifty-seven patients (23%) were HR by Minnesota
criteria, with no significant difference in the proportion of HR patients
between trials (P 5 .27). The median age of HR aGVHD patients was
6 years younger than the SR patients (47 vs 53 years; P 5 .01). There
was no difference in underlying hematologic disease, donor source,
conditioning intensity, or median days to aGVHDonset betweenHR and
SR patients (not shown). Themajority of HR aGVHDpatients had overall
grade 3 aGVHD (9% grade 2, 79% grade 3, and 12% grade 4),
whereas the majority of SR aGVHD patients had overall grade
2 aGVHD (19% grade 1, 76% grade 2, and 5% grade 3; P , .01).
Therewas nomajor skewing of severity within either risk group toward the
extremes of staging. Only 4 patients (2%) with Minnesota SR aGVHD
had isolated stage II lower gastrointestinal (GI) involvement, whereas 15
Minnesota HR patients (26%) had stage II lower GI involvement plus
other organ involvement. Patients with Minnesota HR aGVHD had worse
2-year NRM, in agreement with previous results (supplemental Figure 1).
AREG and aGVHD clinical outcomes
We first examined AREG levels and aGVHD organ involvement. AREG
levels were significantly associated with aGVHD involvement of the
lower GI tract. Patients with stage II-IV lower GI tract involvement had
twofold higher AREG levels at aGVHD onset than those with no lower
GI involvement (median 63 vs 30 pg/mL; P, .01). We next looked at
AREG and overall clinical severity of aGVHD and found that median
AREG levels were 1.7-fold higher in patients with HR aGVHD
compared with SR (53.4 vs 31 pg/mL; P , .01; supplemental
Figure 2). Only 5 patients in this cohort had isolated upper GI aGVHD,
limiting any conclusions about AREG and upper GI aGVHD.
Table 1. Factors associated with day 28 response: univariate analysis
Factor N Day 28 CR/PR (%) OR (95% CI) P Day 28 CR (%) OR (95% CI) P
All patients 251 189 (75) 129 (51)
Trial .11 .78
0302 103 83 (81) 54 (52)
0802 148 106 (72) 75 (51)
Age, y .51 .24
,18 10 8 (80) 6 (60)
18-34 43 29 (67) 19 (44)
35-49 56 41 (73) 24 (43)
$50 142 111 (78) 80 (56)
Donor type .07 .29
HLA-matched sibling 91 72 (79) 53 (58)
Other related 18 17 (94) 11 (61)
URD 120 83 (69) 55 (46)
Mismatched URD 4 2 (50) 1 (25)
UCB 18 15 (83) 9 (50)
Conditioning .32 .32
Myeloablative 161 118 (73) 79 (49)
Reduced-intensity 90 71 (79) 50 (56)
Minnesota aGVHD risk .02 .01
SR 194 153 (79) 108 (56)
HR 57 36 (63) 21 (37)
AREG <.01 .01
First quartile, ,19.8 62 58 (94) 39 (63)
Second quartile, 19.8-33.7 62 46 (74) 34 (55)
Third quartile, 33.8-70.2 64 49 (77) 35 (55)
Fourth quartile, .70.2 63 36 (57) 21 (33)
Continuous variable, OR per doubling in AREG at onset 0.67 (0.56-0.79) <.01 0.76 (0.65-0.89) <.01
AREG, optimal cut point, pg/mL <.01 .01
,33 120 102 (85) 72 (60)
$33 131 87 (66) 57 (44)
Bold values are statistically significant.
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Both the Minnesota risk score and AREG levels at aGVHD diagnosis
were significantly associated with day 28 CR/PR, whereas age,
donor type, and conditioning intensity were not (Table 1). As a
continuous variable, every twofold increase in AREG was associated
with a 33% decrease in the odds of day 28 CR/PR (OR, 0.67; 95%
confidence interval [CI], 0.56-0.79; P , .01). Only one-third of
patients with the highest quartile of AREG (.70.2 pg/mL) had a CR
at day 28. Cox regression showed that as a continuous factor, AREG
was associated with a 27% increase in risk of mortality through 2
years per each doubling in AREG (HR, 1.27; 95% CI, 1.14-1.40).
Using twofold cross-validation, we determined the cutoff at GVHD
onset of AREG for survival was 33 pg/mL. In subsequent analyses, an
AREG of 33 pg/mL or higher is referred to as high AREG, and lower
values are referred to as low AREG.
Minnesota SR aGVHD and AREG
Patients with Minnesota SR aGVHD had an overall 79% day 28 CR/
PR (Table 1), and almost half (92 of 194; 47%) of these patients had
high AREG.Minnesota SR patients with high AREG had a significantly
lower proportion of day 28CR/PR (72% [95%CI, 63%-81%] vs 85%
day 28 CR/PR [78%-92%]; P5 .02; Figure 1) than Minnesota SR
patients with low AREG. In addition, Minnesota SR patients with
high AREG had poorer long-term outcomes with markedly higher
2-year NRM (42% [31%-54%] vs 15% [7%-22%]; P , .01), and
lower 2-year OS (40% [29%-50%] vs 66% [55%-74%]; P , .01;
Figure 2). In logistic regression for the end point of response, Cox
regression on OS and Fine and Gray regression for NRM including
the factors of interest, AREG, and Minnesota risk, controlling for
donor type and age and stratified by study, we found that AREG
was independently associated with a risk of poor clinical outcomes
(Table 2; supplemental Figure 3). Among the Minnesota SR patients,
patients with high AREG showed a 59% decrease in the odds of day
28 CR/PR (OR, 0.41; 95% CI, 0.20-0.84) when compared with
patients with low AREG (reference group). Minnesota SR, high AREG
patients had a twofold increased risk of death (hazard ratio, 2.30; 95%
CI, 1.48-3.58; P , .01; Table 2) and a 3.6-fold higher risk of
2-year NRM (hazard ratio, 3.6; 95% CI, 1.93-6.78; P , .01)
compared with Minnesota SR patients with low AREG (Table 2).
Minnesota HR aGVHD and AREG
Patients with Minnesota HR aGVHD showed a 63% day 28 CR/PR
(Table 1), and over two-thirds (39 of 57; 68%) of Minnesota HR
patients had high AREG. Minnesota HR patients with high AREG
had significantly lower day 28 CR/PR (54% [95%CI, 38%-70%] vs
83% [95% CI, 66%-100%]; P 5 .03; Figure 1) and worse 2-year
NRM (53% [95% CI, 35-71] vs 11% [0%-25%]; P 5 .02) than
Minnesota HR patients with low AREG. OS at 2 years was also
somewhat lower in HR patients with high vs low AREG
(37% ([22%-52%] vs 60% [34%-79%]; P 5 .09 in univariate
analysis). In multivariate regression, patients with high AREG and
Minnesota HR aGVHD had the worst outcomes (Table 2;
supplemental Figure 3). These patients had the lowest likelihood






















Figure 1. Proportion of patients (695% CI) experiencing
clinical end points of day 28 CR/PR, 2-year NRM, and OS
by Minnesota GVHD SR vs HR and plasma AREG at the
onset of aGVHD.
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Figure 2. Patients enrolled in BMT CTN 0302/0802 by AREG plus Minnesota
risk score group. (A) OS and (B) NRM.
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threefold higher risk of death (hazard ratio, 3.35; 95% CI,
1.94-5.79; P , .01; Figure 2A) and a more than sevenfold higher
2-year NRM (hazard ratio, 7.17; 95% CI, 3.40-15.14; P , .01). By
2 years, over half (53% [95% CI, 35%-71%]) of Minnesota HR high
AREG patients experienced NRM, vs only 11% (95% CI, 0%-25%)
of Minnesota HR low AREG patients (P, .01; Figure 2B). Patients
with high AREG also was associated with worse outcomes among
Minnesota HR aGVHD. In a separate analysis using Minnesota HR
aGVHD and low AREG as the reference group, patients with
Minnesota HR aGVHD and high AREG showed a lower likelihood of
response (OR, 0.21; 95% CI, 0.05-0.88; P 5 .03), trended with a
more than twofold higher risk of death (hazard ratio, 2.33; 95% CI,
0.99-5.49; P 5 .05) and a more than sixfold higher 2-year NRM
(hazard ratio, 6.27; 95% CI, 1.26-31.30; P 5 .03).
AREG cutoff in late-onset aGVHD
Testing this AREG$ 33 pg/mL threshold in a separate cohort of 92
late-onset acute GVHD patients,4 we found that high AREG
patients had poorer day 28 responses (55% vs 79% day 28 CR/PR;
P5 .02) and significantly lower 6-month OS (65%with high AREG vs
95% with low AREG; P 5 .01), although there was no difference in
2-year outcomes in this late-onset cohort (P 5 .3; supplemental
Figure 4).
Association of AREG with other aGVHD biomarkers
We found no significant correlation between AREG and our
previously reported circulating angiogenic factors at the onset of
aGVHD including: epidermal growth factor, vascular endothelial
growth factor-A, follistatin, endoglin, angiopoietin-2, and placental
growth factor (Spearman Rho , 0.2 for all comparisons among
patients with samples available for testing).8 In 133 patients with
samples available for testing, AREG was moderately correlated with
previously reported aGVHD biomarkers ST2 (Spearman Rho5 0.47;
95% CI, 0.33-0.59) or REG3a (Spearman Rho 5 0.42; 95% CI,
0.26-0.55; supplemental Figure 5).
Discussion
Using samples from 4 different multicenter cohorts (BMT CTN 0302
and 0802, the Chronic GVHD Consortium, and MAGIC), we have
identified AREG as a biomarker of aGVHD that is highly associated
with clinical outcomes. High AREG concentrations are clinically
predictive for worse day 28 response, OS, and NRM. Furthermore, a
threshold of AREG$ 33 pg/mL further refined the Minnesota clinical
risk score. Almost half (92 of 194; 47%) of Minnesota SR patients
had high AREG levels, and these patients had a low likelihood of
steroid-response and poor survival. Nearly a third (18 of 57; 32%) of
Minnesota HR patients had low AREG levels, and these patients had
a higher likelihood of steroid response. Patients with either Minnesota
HR aGVHD or with high AREG have a low likelihood of response to
steroids, poor NRM, and are in great need of novel therapies. If
validated in additional large series, measurement of AREG at aGVHD
onset may add value in risk-stratifying patients with aGVHD. Patients
from the cohorts analyzed in this study are heterogeneous, including
different ages, diseases, conditioning regimens, and treatments for
aGVHD, which likely adds to the external validity of our results.
The cellular source of circulating AREG in severe aGVHD is not yet
known, although we hypothesize the degree of AREG elevation
reflects the host’s immune response to the severity of tissue
damage caused by aGVHD. Circulating AREG was most strikingly
elevated in Minnesota HR aGVHD, particularly in those with stage
II-IV lower GI involvement. However, AREG was not strongly
correlated with REG3a, an intestinal-specific biomarker, suggesting
that circulating AREG may not be solely of gut origin.
Clinical aGVHD severity as determined by the Minnesota GVHD
risk score and risk as determined by GVHD biomarkers ST2 and
REG3a are currently being used to classify patients as SR or HR
cohorts for GVHD treatment trials, including BMT CTN 1501 for SR
patients (clinicaltrials.gov #NCT02806947). The Minnesota GVHD
risk score is immediately available to the clinician (https://redcap.
ahc.umn.edu/surveys/?s5bNmFhseJIf) and is readily applied using
only bedside measures. It is an informative first step in personalizing
aGVHD therapy, where SR patients may be candidates for less
toxic investigational approaches and HR patients are candidates
for investigational approaches (such as www.clinicaltrials.gov
#NCT02525029).20 However, given that some patients may have
extensive tissue damage or inflammatory responses that are
underestimated by clinical symptoms, GVHD biomarkers may show
their greatest clinical utility in identifying SR patients who are likely
Table 2. AREG, Minnesota risk score, and clinical outcomes: multivariate regression
Factor N OR of CR/PR 95% CI P Hazard ratio of 2-y OS 95% CI P Hazard ratio of 2-y NRM 95% CI P
Minnesota risk/AREG
SR, low AREG 102 1.00* 1.00* 1.00*
SR, high AREG 92 0.41 0.20-0.84 .02 2.30 1.48-3.58 <.01 3.62 1.93-6.78 <.01
HR, low AREG 18 0.89 0.22-3.61 .87 1.44 0.63-3.30 .39 1.14 0.23-5.62 .87
HR, high AREG 39 0.18 0.08-0.44 <.01 3.35 1.94-5.79 <.01 7.17 3.40-15.14 <.01
Age 2 (/decade) 251 1.18 0.96-1.45 .11 1.20 1.05-1.37 .01 1.44 1.19-1.74 <.01
Donor type
HLA-matched sibling 91 1.00* 1.00* 1.00*
Other related 18 4.77 0.58-39.7 .15 1.31 0.63-2.72 .47 1.41 0.58-3.41 .45
URD 124 0.58 0.30-1.15 .12 1.27 0.84-1.91 .26 1.22 0.72-2.07 .46
UCB 18 1.56 0.36-6.67 .55 0.72 0.32-1.64 .44 1.00 0.37-2.71 .99
Bold values are statistically significant.
*Reference group.
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to have poor outcomes. In the present study, we observed that
AREG reclassified nearly half of SR patients into a low steroid
response, high NRM category. The GVHD prognostic algorithm in
current use in clinical trials uses the levels of 2 validated GVHD
biomarkers, ST2 and REG3a, for risk stratification.9,21-23 The limited
correlation of AREG with ST2 and REG3a suggests that AREG
levels are at least partially independent prognostic markers. This
concept is supported by the observation that ST2 and REG3a are
primarily derived from stromal and epithelial cell populations of the
intestine, although the endothelium also contributes to ST2 levels.24
Therefore, it is possible that AREG may improve upon the current
GVHD prognostic algorithm, either as a stand-alone predictor or in
combination with the other biomarkers. This is a topic for future
studies.
Beyond its potential clinical utility as a risk-stratification biomarker,
our observation of elevated AREG in HR aGVHD lends further
evidence to support the notion that aGVHD outcomes may not only
be determined biologically by the donor T-cell–mediated attack, but
also by the host response to that attack. The biology of wound
healing may well be relevant to outcomes of aGVHD. With
accumulating evidence of altered EGFR ligands in aGVHD,4,8,25,26
further investigation into epithelial repair pathways to overcome poor
steroid response is needed. Novel, targeted regenerative therapies,
such as systemic delivery of epithelial growth factors, or delivery
of modified probiotics as luminal “factories” for such growth
factors,27,28 should be tested as adjunctive therapies to standard
immunosuppressive approaches in patients with Minnesota HR
aGVHD, and in Minnesota SR aGVHD with elevated ST2 and
REG3a (ie, AA3 risk) or those with AREG $ 33 pg/mL.
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